Good morning, HealthTech insiders. A 1,105-patient trial is challenging how cardiologists plan stent procedures. Presented at TCT 2026, the P4 trial found that planning procedures using coronary CT scans delivered comparable one-year outcomes to intravascular ultrasound guidance, while cutting median procedure time by 17 minutes and reducing contrast use.
Elsewhere, the FDA has approved VOCERYQ, the first plasmid DNA-based immunotherapy in the U.S., offering a new treatment option for adults with a rare airway disease. And in Australia, amended rules for clinical decision support software took effect on November 1, clarifying which tools qualify for exemption from medical-device registration and requiring their underlying logic to be transparent to clinicians.
In today's Signal:
P4 at TCT 2026: CT-guided PCI planning with Heartflow tools matched IVUS for 12-month target-vessel failure (4.1% vs 4.6%) and cut median procedure time from 63 to 46 minutes.
The FDA grants accelerated approval to INOVIO's VOCERYQ for adults with RRP, the first plasmid DNA-based immunotherapy approved in the U.S., delivered with the CELLECTRA 5PSP device.
Australia's amended clinical decision support software exemption is now in force, with new criteria on diagnosis, treatment decisions and transparent logic.
In partnership with
Read the Top 5 Leadership Books in 1 Week
Reading the five most recommended leadership books cover to cover takes most people a year. With Shortform, it takes a week.
Start with:
Never Split the Difference: how a former FBI hostage negotiator gets to yes
The 7 Habits of Highly Effective People: the principles behind results that last
The 48 Laws of Power: how influence actually works inside organizations
Each guide gives you the key ideas, real examples, and how to apply them at work.
LATEST DEVELOPMENTS
CARDIOVASCULAR IMAGING AI
1. CT-Guided PCI Planning Matches IVUS in the 1,105-Patient P4 Trial at TCT 2026
Heartflow's PCI Navigator combines coronary CT imaging with anatomical and physiological analysis to support stent planning before catheterization. Image credit: Heartflow.
The P4 trial, presented as a late-breaker at TCT 2026 on November 1 and published simultaneously in NEJM, randomized 1,105 patients with stable coronary disease at 23 centers in the US, Europe and Japan to PCI planned with coronary CT or guided by intravascular ultrasound (IVUS). CT guidance was noninferior for 12-month target-vessel failure: 4.1% vs 4.6%.
The details:
The CT arm used Heartflow's FFRCT Analysis and Heartflow Planner, an earlier version of its PCI Navigator. Median procedure time was 46 vs 63 minutes (17 minutes shorter), median contrast 150 vs 170 mL, and advanced calcium modification was used more than twice as often (9.2% vs 3.8%). Per ACC, median age was 65 and nearly 22% of patients were women.
Principal investigator Carlos Collet, MD, PhD, of the Cardiovascular Research Foundation: "P4 shows that non-invasive CT-guided PCI planning achieves comparable clinical outcomes with shorter procedure times and less contrast, enabling interventionalists to anticipate challenges, tailor their strategy, and enter the cath lab better prepared."
In the separate 203-patient NAVIGATE-PCI registry, physicians changed their plan in about 70% of patients after reviewing PCI Navigator versus angiography alone, most often stent length (41%) and lesion preparation (12%). P4 was investigator-initiated and Heartflow-supported. Heartflow (Nasdaq: HTFL) reports use at more than 1,800 institutions.
The Signal: IVUS earned its place by showing that seeing inside the vessel improves outcomes, but it adds time, cost and skill to every case. P4 says much of that planning can happen before the patient is on the table. That moves value from the cath lab catheter to the CT scanner and the software reading it. The open questions are who pays for planning, and whether the result holds in complex lesions and in hospitals without strong CT programs.
DNA MEDICINES
2. The FDA Approves VOCERYQ, the First Plasmid DNA-Based Immunotherapy in the U.S.
INOVIO's DNA medicine platform uses engineered plasmids and CELLECTRA electroporation technology to deliver genetic instructions into cells. Image credit: INOVIO Pharmaceuticals.
On October 30, the FDA granted accelerated approval to INOVIO's VOCERYQ (previously INO-3107) to reduce the frequency of surgery in adults with recurrent respiratory papillomatosis (RRP), a rare disease in which HPV types 6 and 11 drive wart-like growths in the airway. The FDA calls it the first plasmid DNA-based immunotherapy approved in the U.S.
The details:
VOCERYQ uses DNA plasmids encoding HPV-6 and HPV-11 antigens, plus a second plasmid encoding the immune signal IL-12 per the prescribing information, given by intramuscular injection with INOVIO's CELLECTRA 5PSP device, which uses brief electrical pulses (electroporation) to get the DNA into cells. Four doses, three weeks apart, follow a standard debulking surgery, a 9-week dosing regimen.
In the open-label RRP-001 study of 32 adults, 7 of 26 patients in the efficacy population (27%) needed no surgery in the 12 months after treatment. Those 26 had a median of 4.5 surgeries in the prior year. Because approval is accelerated, the FDA requires a confirmatory study and wants a draft protocol by the end of 2026.
INOVIO expects to take orders and ship in about 60 days, with full field deployment in Q1 2027, supported by Syneos Health. CEO Jacqueline Shea, PhD: VOCERYQ is "designed to deliver what we understand matters most to patients, which is the reduction of the surgical burden caused by RRP." It enters a market where Precigen's PAPZIMEOS won full FDA approval in August 2025.
The Signal: This is a device and a drug approved as one product, and that is the HealthTech story. DNA medicines avoid the viral vectors and lipid nanoparticles that limit other genetic approaches, but they need a delivery device in every clinic that uses them. VOCERYQ arrives second, with a lower published complete response rate than the therapy already on the market and a confirmatory trial still to run. Its case will rest on the patient experience, the delivery logistics and how payers compare the two.
CLINICAL AI
3. Australia's Amended Exemption for Clinical Decision Support Software Takes Effect
An Australian Therapeutic Goods Administration decision chart illustrates how software functionality influences regulatory classification. Amendments to Australia's clinical decision support software exemption took effect on November 1, 2026. Image credit: Therapeutic Goods Administration.
Amendments to the TGA's exemption for clinical decision support software (CDSS) came into force on November 1, under the Therapeutic Goods Legislation Amendment (2026 Measures No. 1) Regulations 2026. Software that meets every criterion is exempt from inclusion on the Australian Register of Therapeutic Goods (ARTG).
The details:
Two new criteria stand out. Exempt software must not be intended to provide a diagnosis or treatment decision, including IVD software. It must also display the guidelines, calculations or logic behind its output, so a health professional can readily interpret and verify the recommendation. The image and signal criterion now names compressing and decompressing alongside processing and analysing.
The TGA says the amendments "do not change the scope of the CDSS exemption or introduce new regulatory requirements." The regulation applies to software made before November 1 that is intended for use on or after it, so there is no transition period. The changes follow a 2024 consultation.
It lands two weeks after the TGA's digital scribe review, published October 16. Of 12 AI scribe products examined, 8 likely meet the medical device definition, 2 need more information and 2 are unlikely to qualify. None of the 12 was on the ARTG, and the TGA declined to say which 8 are likely devices.
The Signal: The new transparency criterion is the one to watch. A rules engine can show its logic. A large language model producing a recommendation mostly cannot, at least not in the readable way the exemption asks for. That pushes generative tools that suggest diagnoses or treatments toward full device regulation, and it gives buyers a simple question to ask any vendor: can my clinician see why it said that?
QUICK HITS
👀 WHAT WE'RE WATCHING NEXT
BRAVEHEART at TCT, Nov 3: Heartflow's registry of 96 asymptomatic firefighters, with plaque found in 72% and severe plaque volume in 16%, tests whether CT plaque analysis moves prevention as well as procedures. Watch whether the 68% who said they would start lipid-lowering therapy is followed by data on who actually did.
INOVIO's launch call, Nov 2: INOVIO hosts a call at 8:00 AM ET (1:00 PM Lisbon) on label details and commercialization. Watch for price, how many treatment sites will have CELLECTRA devices, and the confirmatory study design.
Who adopts the TGA transparency test: Whether Australian AI scribe and decision support vendors start publishing how their tools show their logic, whether any of them lists on the ARTG, and whether the TGA names the 8 scribe products it considers likely devices.
💰 FOLLOW THE MONEY
The deals:
Surgery Partners: HealthSpan Partners, backed by Bon Secours Mercy Health, agreed on October 26 to take Surgery Partners private in an approximately $5.7B deal at $23.50 per share, with Bain Capital rolling over its roughly 39% stake.
NeuroXess: The Chinese brain-computer interface developer raised RMB 700M (~$105M) in Series B funding on October 28 to advance registration trials of its brain implant.
Intake Breathing: Secured $62M from Camino Partners to scale its magnetic nasal dilator business.
The pattern: The week's funding activity, highlighted in Axios Pro's October 31 roundup and company announcements, points toward scale and hardware. Surgery Partners represents consolidation in healthcare delivery, NeuroXess is advancing implanted neurotechnology toward regulatory approval, and Intake Breathing is attracting growth capital for consumer medical-adjacent hardware. Meanwhile, INOVIO's first product approval shifts attention from research funding to commercialization. VOCERYQ's pricing will be the next number to watch.
📆 UPCOMING HEALTHTECH EVENTS
AHA Scientific Sessions 2026: November 6 to 9, 2026 · McCormick Place, Chicago, IL
Cardiology's next big stage after TCT, where CT plaque analysis, prevention and cardiovascular AI data will keep the P4 debate going.
Web Summit 2026: November 9 to 12, 2026 · MEO Arena and FIL, Lisbon, Portugal
Europe's largest technology conference, with health and AI founders and investors in one place in our home city.
ESC Digital & AI Summit 2026: November 12 to 13, 2026 · Basel, Switzerland
The European Society of Cardiology's meeting for engineers, data scientists and clinicians building and validating AI for cardiovascular care.
🛠️ Trending HealthTech AI Tools
Philips HyperVue Integrated System. Launched in the U.S. on Oct 30: an integrated cath lab system that combines DeepOCT+NIRS coronary imaging with X1-FFR, an FDA-cleared, AI-based FFR derived from a single angiographic view. A useful contrast to P4: Philips is investing in better imaging inside the lab.
Cleerly LABS and Cleerly PLAQUE. FDA-cleared update announced Oct 30. The plaque algorithm is now trained with CONFIRM2 registry data, about 50% female and 6,550 people from 46 countries. Cleerly says it will be available in November 2026.
AEYE-DS. AEYE Health's AI diabetic retinopathy screening system, named Best Digital Health Solution at the 2026 Prix Galien USA awards (announced Oct 30). Built for screening in primary care, where most people with diabetes are seen.
🛠️ Trending HealthTech AI Startups
Science Corporation: Named Best Startup in Medical Technology and Digital Health at the 2026 Prix Galien USA awards (announced Oct 30). Science builds neural engineering and brain-computer interface technology. Strategic interest: implanted neurotech is drawing capital this week, from Science's award to NeuroXess's Series B.
Strand Therapeutics: Named Best Startup in Biotechnology at the 2026 Prix Galien USA awards (announced Oct 30). Strand develops programmable mRNA therapies. Strategic interest: genetic medicine platforms are competing on delivery and control, the same axis on which INOVIO's DNA approach competes.
Intake Breathing: The maker of a magnetic nasal dilator took $62M from Camino Partners, announced Oct 28, to push into mass retail. Strategic interest: consumer breathing and sleep devices are attracting growth capital outside the regulated device channel.
DECISION INTELLIGENCE
Highlights: Deep Dives & Industry Reports
1. Planning Moves Upstream: What the P4 Trial Means for CT, IVUS and the Economics of the Cath Lab. A 1,105-patient noninferiority result, a 70% plan-change registry and an open payment question: where value moves if PCI planning leaves the cath lab.
2. Device and Drug as One Product: VOCERYQ, CELLECTRA and the Commercial Test for DNA Medicines. The first U.S. plasmid DNA immunotherapy arrives second to market, with an accelerated label and a delivery device in every treatment room. What decides whether it wins.
3. Show Your Working: Australia's CDSS Exemption, the AI Scribe Review and the Transparency Test for Clinical AI. New criteria on diagnosis, treatment decisions and visible logic, plus 8 of 12 scribes likely devices: what changed on November 1 and who is exposed.
Which of this weekend's moves is most likely to change clinical practice within two years?
That's it for today!
A CT scan that plans the stent, a DNA medicine that needs a device in the room, and a regulator asking software to show its working. Each one moves a decision earlier, before the catheter, before the next surgery, before the clinician accepts a suggestion.
Here is the tension: the earlier a decision is made, the less anyone can see it being made. Who is responsible for checking it, and who pays for that check?
How did we do today?
See you tomorrow,
Dr. Dereck Mush, MD, MBA
The HealthTech Signal is independently funded. Sponsorships help us invest in better reporting, research, and a stronger newsletter for our readers. Want to reach HealthTech founders & executives while supporting the Signal? Get in touch.
Was this email forwarded to you? Sign up here.
Until tomorrow,
The HealthTech Signal
